Search results
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
BioPharma Dive· 5 days agoThe Swiss pharma is paying Dren Bio $150 million to partner on “targeted myeloid engagers.”...
The Swiss pharma is paying Dren Bio $150 million to partner on “targeted myeloid engagers.”...